BANK VONTOBEL/CALL/GILEAD SCIENCES/84/0.025/21.06.24

BANK VONTOBEL/CALL/GILEAD SCIENCES/84/0.025/21.06.24 Share Price

Warrant

WGIBBV

CH1236758350

Real-time Bid/Ask 11:33:01 28/05/2024 am IST
0.002 ^CHF / 0.02 ^CHF	-45.00%

1 month	-86.30%
3 months	-61.54%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart GILEAD SCIENCES, INC.

Chart BANK VONTOBEL/CALL/GILEAD SCIENCES/84/0.025/21.06.24

Latest news about GILEAD SCIENCES, INC.

Gilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024	22/05	BU
Gilead Sciences - Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis	20/05	AQ
Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis	18/05	BU
Transcript : Gilead Sciences, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-15-2024 10:30 AM	15/05

More news

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	GILEAD SCIENCES, INC.
Issuer	Vontobel
	WGIBBV
ISIN	CH1236758350
Date issued	06/01/2023
Strike	84 $
Maturity	21/06/2024 (25 Days)
Parity	40 : 1
Emission price	0.32 CHF
Emission volume	N/A
Settlement	physical
Currency	CHF

Technical Indicators

Highest since issue	0.35 CHF
Lowest since issue	0.02 CHF
Spread	0.018 CHF
Spread %	90.00%

Company Profile

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).

Sector

More about the company